We are live on
!
Find out more
OPPM
Opus Point Partners Management Portfolio holdings
AUM
$55.3M
1-Year Est. Return
7.48%
This Fund
S&P 500
This Quarter
Est. Return
-19.07%
1 Year Est. Return
-7.48%
3 Year Est. Return
+85.18%
5 Year Est. Return
+168.21%
10 Year Est. Return
–
AUM
$129M
AUM Growth
-$22M
(-15%)
Cap. Flow
-$11.1M
Cap. Flow
% of AUM
-8.62%
Top 10 Holdings %
Top 10 Hldgs %
47.53%
Holding
65
New
8
Increased
16
Reduced
26
Closed
13
Avg Time Held Equity + Options
3.2
quarters
Top 10 Avg Time Held Equity + Options
0.6
quarters
Top 20 Avg Time Held Equity + Options
3.5
quarters
Avg Time Held Equity only
3.3
quarters
Top 10 Avg Time Held Equity only
0.7
quarters
Top 20 Avg Time Held Equity only
3.5
quarters
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Pfizer
PFE
|
+$3.31M |
| 2 |
ProShares Ultra NASDAQ Biotechnology
BIB
|
+$2.19M |
| 3 |
Alnylam Pharmaceuticals
ALNY
|
+$1.82M |
| 4 |
ONCE
Spark Therapeutics, Inc. Common Stock
ONCE
|
+$994K |
| 5 |
ProShares UltraShort S&P500
SDS
|
+$967K |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
iShares Biotechnology ETF
IBB
|
+$10.7M |
| 2 |
Gilead Sciences
GILD
|
+$2.74M |
| 3 |
NSTG
NanoString Technologies, Inc.
NSTG
|
+$1.5M |
| 4 |
Xencor
XNCR
|
+$1.32M |
| 5 |
Amgen
AMGN
|
+$1.28M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 73.12% |
| 2 | Miscellaneous | 26.17% |
| 3 | Real Estate | 0.72% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
1
PUT
iShares Russell 2000 ETF
IWM
$78.3B
| $22.1M | 17.11% |
+200,000
| New | +$20.7M |
2016 Q1
0 quarters
|
|
2
Bristol-Myers Squibb
BMY
$118B
| $4.92M | 3.81% |
77,100
| – | – |
2015 Q3
2 quarters
|
|
|
MDVN
3
DELISTED
MEDIVATION, INC.
MDVN
| $4.89M | 3.78% |
106,358
+15,048
| +16% | +$546K |
2014 Q4
5 quarters
|
|
|
4
Alnylam Pharmaceuticals
ALNY
$30.4B
| $4.87M | 3.77% |
77,593
+27,371
| +55% | +$1.82M |
2014 Q4
5 quarters
|
|
5
Merck
MRK
$359B
| $4.76M | 3.68% |
94,320
| – | – |
2015 Q3
2 quarters
|
|
|
6
Amgen
AMGN
$226B
| $4.08M | 3.15% |
27,184
-8,589
| -24% | -$1.28M |
2014 Q4
5 quarters
|
|
7
BioMarin Pharmaceuticals
BMRN
$10.7B
| $3.98M | 3.08% |
48,260
+4,390
| +10% | +$357K |
2014 Q4
5 quarters
|
|
|
CELG
8
DELISTED
Celgene Corp
CELG
| $3.96M | 3.06% |
39,596
-8,360
| -17% | -$861K |
2014 Q4
5 quarters
|
|
9
Nektar Therapeutics
NKTR
$1.36B
| $3.96M | 3.06% |
19,211
-4,028
| -17% | -$774K |
2014 Q4
5 quarters
|
|
10
Ionis Pharmaceuticals
IONS
$7.26B
| $3.92M | 3.03% |
96,808
-5,651
| -6% | -$230K |
2014 Q4
5 quarters
|
|
|
SGEN
11
DELISTED
Seagen Inc. Common Stock
SGEN
| $3.86M | 2.98% |
109,922
-17,166
| -14% | -$577K |
2014 Q4
5 quarters
|
|
12
Incyte
INCY
$22.6B
| $3.75M | 2.9% |
51,677
+3,632
| +8% | +$271K |
2014 Q4
5 quarters
|
|
|
ALXN
13
DELISTED
Alexion Pharmaceuticals
ALXN
| $3.54M | 2.73% |
25,405
-7,564
| -23% | -$1.11M |
2014 Q4
5 quarters
|
|
14
Illumina
ILMN
$41.8B
| $3.52M | 2.72% |
22,337
-940
| -4% | -$144K |
2014 Q4
5 quarters
|
|
15
Alkermes
ALKS
$6.75B
| $3.5M | 2.7% |
102,277
+14,862
| +17% | +$587K |
2014 Q4
5 quarters
|
|
16
Mettler-Toledo International
MTD
$31.3B
| $3.27M | 2.53% |
9,500
-200
| -2% | -$64.4K |
2014 Q4
5 quarters
|
|
17
Vertex Pharmaceuticals
VRTX
$129B
| $3.27M | 2.53% |
41,137
-525
| -1% | -$47.5K |
2014 Q4
5 quarters
|
|
|
18
Pfizer
PFE
$162B
| $3.26M | 2.52% |
+115,940
| New | +$3.31M |
2016 Q1
0 quarters
|
|
19
Regeneron Pharmaceuticals
REGN
$78.5B
| $3.22M | 2.49% |
8,929
-1,785
| -17% | -$736K |
2014 Q4
5 quarters
|
|
|
QGENF
20
DELISTED
QIAGEN NV
QGENF
| $3.02M | 2.33% |
135,000
-25,000
| -16% | -$559K |
2014 Q4
5 quarters
|
|
21
Biogen
BIIB
$33.9B
| $2.9M | 2.24% |
11,125
+643
| +6% | +$170K |
2014 Q4
5 quarters
|
|
|
22
ProShares Ultra NASDAQ Biotechnology
BIB
$91.4M
| $2.63M | 2.04% |
64,462
+49,543
| +332% | +$2.19M |
2014 Q4
5 quarters
|
|
|
EPZM
23
DELISTED
Epizyme, Inc
EPZM
| $2.3M | 1.78% |
189,564
+53,937
| +40% | +$546K |
2014 Q4
5 quarters
|
|
24
AstraZeneca
AZN
$246B
| $2.23M | 1.72% |
39,550
+15,000
| +61% | +$901K |
2015 Q2
3 quarters
|
|
25
Agios Pharmaceuticals
AGIO
$1.84B
| $2.07M | 1.6% |
51,000
+17,000
| +50% | +$727K |
2015 Q3
2 quarters
|
|
Similar funds
KIA
PGA
GX
SCG
TCMV
FCM
DP
SAM
Opus Point Partners Management's Q1 2016 Portfolio in Review
As of Q1 2016, Opus Point Partners Management held 65 positions worth $129M, down 15% from $151M the previous quarter. Its ten largest holdings account for 48% of the portfolio.
Opus Point Partners Management withdrew a net $11.1M in Q1 2016, closing 13 positions and reducing 26 holdings. Its most notable exit was iShares Biotechnology ETF, an estimated $10.7M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 73% of assets, down from 85% a quarter earlier, followed by Miscellaneous and Real Estate.
Against the trend, Opus Point Partners Management opened a new position in Pfizer worth $3.26M.
- Opus Point Partners Management's largest Q1 2016 buy was Pfizer: 115,940 shares worth $3.26M.
- Opus Point Partners Management added most to ProShares Ultra NASDAQ Biotechnology in Q1 2016, an estimated $2.19M increase.
- Opus Point Partners Management's biggest Q1 2016 reduction was Gilead Sciences, cutting an estimated $2.74M.
- Opus Point Partners Management fully exited iShares Biotechnology ETF in Q1 2016, selling an estimated $10.7M.
- Opus Point Partners Management's ten largest holdings make up 48% of its $129M portfolio in Q1 2016.
- Opus Point Partners Management opened 8 new positions and closed 13 in Q1 2016.
- Opus Point Partners Management's portfolio value fell 15% quarter-over-quarter to $129M.
Based on Opus Point Partners Management's 13F filing for Q1 2016, filed 13 May 2016.